HUTCHMED Posts $457M Net Income on ATTC Platform Progress and Global Expansion
Event summary
- HUTCHMED reported $457M net income for 2025, driven by profitable core operations and a $416M divestment gain.
- FRUZAQLA® ex-China sales grew 26% to $366M, while ELUNATE® China sales recovered with 33% H2 growth.
- ATTC platform advanced with first clinical trial for HMPL-A251 in December 2025 and two more candidates in 2026.
- Savolitinib triggered $11M milestone from AstraZeneca for third lung cancer indication approval in China.
- Company maintains $1.4B cash position and guides for $330M-$450M oncology revenue in 2026.
The big picture
HUTCHMED's strong 2025 results reflect its strategic pivot toward global expansion and next-generation ATTC technology. The company's ability to navigate China's regulatory headwinds while advancing its innovative pipeline positions it as a key player in the competitive oncology market. With $1.4B in cash and a robust late-stage pipeline, HUTCHMED is well-positioned to capitalize on emerging opportunities in targeted therapies and immunotherapies.
What we're watching
- ATTC Platform Scaling
- Whether HUTCHMED can successfully partner its ATTC candidates with multinational pharma companies in 2026.
- China Market Recovery
- The pace at which HUTCHMED can sustain its China sales recovery across ELUNATE, SULANDA, and ORPATHYS.
- Regulatory Momentum
- How the upcoming regulatory decisions for sovleplenib and fanregratinib will impact HUTCHMED's near-term revenue visibility.
Related topics